Imugene Ltd (ASX:IMU, OTC:IUGNF) has welcomed the acceptance of an abstract on the overall survival results from its HER-Vaxx HERIZON study for presentation at the ESMO Asia Congress 2022, to be held in Singapore from December 2-4, 2022.
The annual event brings together cancer professionals from around the world to present and discuss the latest scientific and clinical advances from across the field of oncology.
Principal investigator of the study Marina Maglakelidze will present the abstract titled 'HERIZON Overall Survival Results: A study of IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing Metastatic or Advanced Gastric/GEJ Cancer', as part of a session on gastrointestinal tumours on December 4, 2022.
Targeting gastric and esophagus cancers
The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing advanced/metastatic gastric/esophagus (GEJ) cancer.
HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.
Imugene will announce data and information to be presented as part of ESMO in late November.
Well resourced
Imugene is a well-funded clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
The company’s unique platform technologies seek to harness the body’s immune system against tumours, to potentially achieve a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard-of-care drugs and emerging immunotherapies such as CAR T’s for solid tumours.